Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Leukemia 10Recurrence 9Lymphoproliferative Disorders 6Neoplasm, Residual 5Lymphatic Diseases 5Burkitt Lymphoma 5Lymphoma, Non-Hodgkin 4Immunoproliferative Disorders 4Neoplasms 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Leukemia, Lymphoid 2Bites and Stings 2Neoplasms by Histologic Type 1Lymphoma 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Blast Crisis 1

Interventions

nilotinib 50Imatinib Mesylate 48Dasatinib 25bosutinib 18asciminib 17ponatinib 10Homoharringtonine 5Cytarabine 4olverembatinib 3Interferon-alpha 3Decitabine 3tozasertib 2peginterferon alfa-2a 2flumatinib 2fludarabine phosphate 2ON 01910 2Mycophenolic Acid 2Melphalan 2Interferon alpha-2 2Filgrastim 2Cyclophosphamide 2Bone Marrow Transplantation 2BID protein, human 2Azacitidine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2vosaroxin 1troxacitabine 1triciribine 1terameprocol 1sonidegib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × blinatumomab × Clear all
NCT04260022 2025-11-05

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Ascentage Pharma Group Inc.

Phase 1 Recruiting
242 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Burkitt Lymphoma, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡